Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
By D. Siegal, J. Curnutte, S. Connolly, Genmin Lu, P. Conley, B. Wiens, Vandana S. Mathur, J. Castillo, M. Bronson, J. Leeds and 3 more. New England Journal of Medicine, 2015
1,005 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/563cf754b0bd5a4eaf65f6a57a4342e1f19e4d35
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Hematology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition (2016, background): “Specific antidotes against Xa antagonists are in development, including andexanet 17 alfa, a specific factor Xa inhibitor-reversing agent [629], however, these are not yet approved 18 for clinical use [630, 631].”
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors (2019, neutral): “Restart of any anticoagulation§ 220 (62) 145 (41) 46 (13) 29 (8)”
- The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition (2019, background): “2018, the US Food and Drug Administration (FDA) approved andexanet alpha [754] as an antidote for the”
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “tion and for the duration of infusion, with a transient increase in markers of coagulation activity of uncertain clinical relevance.(508) Another agent under development is ciraparantag (PER977), an antidote”